ARID1A and neoplasm: Higher-risk patients had fewer mutations in LRP1B, SYNE1, and ARID1A (Supplementary Figure 1A, 1B), while those with lower risk-scores obtained a increased tumor mutational burden (TMB) (P < 0.001, Supplementary Figure 1C), suggesting that the low-risk group might be immune-sensitive since a high TMB might be linked to an inflammatory tumor immune microenvironment (TIME) and preferable sensitivity to immune checkpoint inhibitors (ICIs) [16].